Femasys (NASDAQ:FEMY) Price Target Raised to $12.00

Femasys (NASDAQ:FEMYGet Free Report) had its price target hoisted by equities researchers at HC Wainwright from $10.00 to $12.00 in a research note issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other equities analysts also recently weighed in on FEMY. Jonestrading boosted their price target on Femasys from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Chardan Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research note on Thursday, March 21st.

Check Out Our Latest Stock Report on FEMY

Femasys Trading Up 5.4 %

Shares of NASDAQ:FEMY opened at $1.55 on Monday. The company’s 50-day moving average price is $1.41 and its two-hundred day moving average price is $1.22. Femasys has a one year low of $0.25 and a one year high of $4.75. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.68 and a quick ratio of 4.40. The stock has a market capitalization of $33.56 million, a PE ratio of -1.68 and a beta of -3.00.

Femasys (NASDAQ:FEMYGet Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.19) EPS for the quarter, meeting the consensus estimate of ($0.19). The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.30 million. Femasys had a negative return on equity of 119.80% and a negative net margin of 1,329.10%. On average, equities analysts forecast that Femasys will post -0.74 EPS for the current fiscal year.

Institutional Trading of Femasys

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. acquired a new position in Femasys during the 1st quarter worth approximately $269,000. Barclays PLC bought a new stake in shares of Femasys during the third quarter worth about $295,000. Northern Trust Corp acquired a new position in shares of Femasys in the fourth quarter valued at approximately $77,000. Schonfeld Strategic Advisors LLC acquired a new position in Femasys in the 3rd quarter valued at approximately $199,000. Finally, UBS Group AG increased its holdings in Femasys by 6,394.8% in the first quarter. UBS Group AG now owns 66,702 shares of the company’s stock valued at $151,000 after purchasing an additional 65,675 shares during the period. 65.27% of the stock is currently owned by institutional investors.

About Femasys

(Get Free Report)

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

See Also

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.